TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor that recognizes changes in the lipid microenvironment, which may occur during amyloid β (Aβ) accumulation and neuronal degeneration in Alzheimer’s disease (AD). Rare TREM2 variants that affect TREM2 function lead to an increased risk of developing AD. In murine models of AD, TREM2 deficiency prevents microglial clustering around Aβ deposits. However, the origin of myeloid cells surrounding amyloid and the impact of TREM2 on Aβ accumulation are a matter of debate. Using parabiosis, we found that amyloid-associated myeloid cells derive from brain-resident microglia rather than from recruitment of peripheral blood monocytes. To determine the impact of TREM2 deficiency on Aβ accumulation, we examined Aβ plaques in the 5XFAD model of AD at the onset of Aβ-related pathology. At this early time point, Aβ accumulation was similar in TREM2-deficient and -sufficient 5XFAD mice. However, in the absence of TREM2, Aβ plaques were not fully enclosed by microglia; they were more diffuse, less dense, and were associated with significantly greater neuritic damage. Thus, TREM2 protects from AD by enabling microglia to surround and alter Aβ plaque structure, thereby limiting neuritic damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which may represent dystrophic neurons that accumulate over time as a result of ineffective microglial control of AD pathology due to lack of Trem218,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the compaction of protofibrillary Aβ into a dense core plaque, which requires apoE and is promoted by TREM2 (Bales et al., 1997b, 1999; Bien-Ly et al., 2012; Wang et al., 2016; Yuan et al., 2016), could be a protective mechanism that limits neurotoxicity of amyloid deposits once they start to build up in the aging brain.”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trem2 deficiency induces dynamic changes but an eventual increase in plaque and neuritic pathology (Jay et al., 2017; Wang et al., 2015; Wang et al., 2016; Yuan et al., 2016).”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of TREM2 results in impaired plaque trimming, which leads to enlarged plaques with reduced compaction48,49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [48]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 4×
“Brains were isolated 3 h after injection and made into single-cell suspension as previously described (Heneka et al., 2013).”
BackgroundMethodInfluentialIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“However, phenotypic markers of migroglia, such as low expression of CD45 and high expression of the P2Y(12) receptor, are altered upon microglial activation and therefore do not precisely discriminate microglia from monocytes (Butovsky et al., 2014).”
BackgroundTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 11×
“…response to Aβ deposits in all AD models, changes in Aβ burden develop more slowly; therefore, the discrepancies in Aβ accumulation may be a result of the varied timing of the analyses—8 mo in 5XFAD mice (Wang et al., 2015) and 3–4 mo in APP PS1-21 mice (Ulrich et al., 2014; Jay et al., 2015).”
BackgroundMethodResultInfluentialSelf-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 1×
“Key pathological features of AD consist of the deposition of amyloid-β peptide (Aβ) and hyperphosphorylated tau aggregates that, together, are linked with synapse loss and neuronal cell death, as well as activation of microglia and astrocytes (Holtzman et al., 2011).”
BackgroundSelf-citationAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“Recent genome-wide association studies have identified rare variants of genes that encode immune receptors as risk factors (Guerreiro and Hardy, 2014; Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“Given that brain-resident microglia are capable of self-renewal and expansion (Gomez Perdiguero et al., 2013; Greter and Merad, 2013; Prinz and Priller, 2014), we next sought to determine if microglia associated with plaques resulted from the proliferation of resident microglia.”
BackgroundTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124 · cited 2×
“TREM2 signaling promotes survival, proliferation, phagocytosis, and secretion of cytokines and chemokines (Takahashi et al., 2005; Otero et al., 2009; Wang et al., 2015).”
BackgroundThe Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727 · cited 2×
“The origin of nonfamilial AD is less well understood and may depend on a combination of genetic and nongenetic risk factors (Tanzi, 2012).”
Background
Cited by
Items 401–500 of 838
Microglia and its Genetics in Alzheimer's Disease
Liang, X., Wu, H., Colt, M., Guo, X., Pluimer, B. R., Zeng, J., Dong, S., & Zhao, Z. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211105140732 · Cited by 36
Prevention of Alzheimer's disease through diet: An exploratory review
Bhuiyan, N. Z., Hasan, M. K., Mahmud, Z., Hossain, M. S., & Rahman, A. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100257 · Cited by 37
“This can also cause neural damage in AD because, in Alzheimer ’ s, the numbers of A β plaques are so high [51].”
BackgroundYan, H., Wang, W., Cui, T., Shao, Y., Li, M., Fang, L., & Feng, L. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s455881 · Cited by 33
Tsering, W., de la Rosa, A., Ruan, I. Y., Philips, J. L., Bathe, T., Villareal, J. A. B., & Prokop, S. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16275 · Cited by 34
“…with an increased risk of developing AD were associated with reduced microglia clustering, increased neuritic dystrophy, and overall tau burden in animal models as well as human postmortem tis - sue (Leyns et al., 2019 ; Prokop, Miller, et al., 2019; Wang et al., 2016; Yuan et al., 2016 ).”
Du, S., Ou, F., Drieu, A., Xu, E. Z., Cheng, Y., Storck, S. E., Mamuladze, T., Cao, J., Abduljawad, N., Bhattarai, B., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.01.032 · Cited by 37
Self-citationKong, Y., Huang, L., Li, W., Liu, X., Zhou, Y., Liu, C., Zhang, S., Xie, F., Zhang, Z., Jiang, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.609908 · Cited by 29
“Typical pathological features of AD include senile plaques and neurofibrillary tangles (Ulrich et al., 2014; Wang et al., 2016).”
BackgroundPlasticity of human microglia and brain perivascular macrophages in aging and Alzheimer’s disease
Lee, D., Vicari, J. M., Porras, C., Spencer, C., Pjanic, M., Wang, X., Kinrot, S., Weiler, P., Kosoy, R., Bendl, J. M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02716-6 · Cited by 36
Ketone body metabolism and the NLRP3 inflammasome in Alzheimer's disease
Shippy, D. C., Evered, A. H., & Ulland, T. K. (2024) · Immunological Reviews · doi:10.1111/imr.13365 · Cited by 36
Self-citationPersonalizing the Care and Treatment of Alzheimer’s Disease: An Overview
Štrac, D. Š., Konjevod, M., Šagud, M., Perković, M. N., Erjavec, G. N., Vuić, B., Šimić, G., Vukić, V., Mimica, N., & Pivac, N. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s284615 · Cited by 38
“lation of Aβ and loss of neurons in the mouse model of AD.(51,52) Transcriptome profiling additionally identified”
BackgroundQin, Q., Wan, H., Wang, D., Li, J., Qu, Y., Zhao, J., Li, J., & Xue, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.892493 · Cited by 31
“In addition, the reduction in CSF sTREM2 in Aβ pathology may be due to microglia initially form a barrier around Aβ plaques and CSF sTREM2 released by microglia is retained within the plaque barrier (Condello et al., 2015; Wang et al., 2016).”
BackgroundVautheny, A., Duwat, C., Aurégan, G., Joséphine, C., Hérard, A.-S., Jan, C., Mitja, J., Gipchtein, P., Gaillard, M.-C., Buée, L., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105398 · Cited by 28
TREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges
Zgórzyńska, E. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103917 · Cited by 30
Castellano, J. M., Palner, M., Li, S., Freeman, G. M., Nguyen, A., Shen, B., Stan, T. M., Mosher, K. I., Chin, F. T., de Lecea, L., et al. (2016) · Scientific Reports · doi:10.1038/srep29015 · Cited by 31
Diesel exhaust impairs TREM2 to dysregulate neuroinflammation
Greve, H. J., Mumaw, C. L., Messenger, E. J., Kodavanti, P. R. S., Royland, J. L., Kodavanti, U. P., & Block, M. L. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02017-7 · Cited by 30
“Murine studies have revealed that TREM2 regulates microglia-mediated responses to neurodegenerative processes [22], such as the chemotactic microglial response to amyloid plaques [25], the pro-inflammatory response of microglia [23], microglial survival [26], and the disease-associated microglia (DAM) phenotype [27].”
BackgroundAnimal models of Alzheimer’s disease: preclinical insights and challenges
Xu, Q., Yang, W., Zhong, M., Lin, Z., Gray, N. E., & Xian, Y. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0001 · Cited by 44
Fernández Zapata, C., Giacomello, G., Spruth, E. J., Middeldorp, J., Gallaccio, G., Dehlinger, A., Dames, C., Leman, J. K. H., van Dijk, R. E., Meisel, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34719-2 · Cited by 27
Chen, K., Li, F., Zhang, S., Chen, Y., Ikezu, T. C., Li, Z., Martens, Y. A., Qiao, W., Meneses, A. D., Zhu, Y., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03420-8 · Cited by 35
“TREM2 has been shown to play a key role in regulating microglial responses to Aβ deposition in many studies using amyloid mouse models [47–50].”
Convergent molecular defects underpin diverse neurodegenerative diseases
Tofaris, G. K., & Buckley, N. J. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316988 · Cited by 31
Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer’s Disease
Liu, C., & Yu, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00297 · Cited by 27
“A possible reason would be that a part of sTREM2 released from microglia is retained within the barrier formed by microglia around plaques in the late stage of AD (Condello et al., 2015; Wang et al., 2016).”
BackgroundSTING Deletion Protects Against Amyloid β‐induced Alzheimer's Disease Pathogenesis
Thanos, J. M., Campbell, O. C., Cowan, M. N., Bruch, K. R., Moore, K. A., Ennerfelt, H. E., Natale, N. R., Mangalmurti, A., Kerur, N., & Lukens, J. R. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70305 · Cited by 26
Cai, Y., Kanyo, J. E., Wilson, R. S., Bathla, S., Cardozo, P. L., Тонг, Л., Qin, S., Fuentes, L. A., Pinheiro‐de‐Sousa, I., Huynh, T., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00823-3 · Cited by 28
“In contrast, in AD, PAASs persist for very long intervals without significant glial clearance 4,30–32 .”
Self-citationParkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy
Guo, X., Song, D., Wu, M., Zhang, J., Li, J., & Yuan, L. (2025) · MedComm · doi:10.1002/mco2.70540 · Cited by 37
Microglia in Alzheimer’s Disease
Süß, P., & Schlachetzki, J. C. M. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200212155234 · Cited by 27
Microglia in CNS infections: insights from Toxoplasma gondii and other pathogens
Cowan, M. N., Sethi, I., & Harris, T. H. (2022) · Trends in Parasitology · doi:10.1016/j.pt.2021.12.004 · Cited by 28
Neurodegenerative phagocytes mediate synaptic stripping in Neuro-HIV
Liberto, G. D., Égervári, K., Kreutzfeldt, M., Schürch, C. M., Hewer, E., Wagner, I., Pasquier, R. D., & Merkler, D. (2022) · Brain · doi:10.1093/brain/awac102 · Cited by 28
Let’s make microglia great again in neurodegenerative disorders
Guillot‐Sestier, M., & Town, T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1792-x · Cited by 31
Association study of serum soluble TREM2 with vascular dementia in Chinese Han population
Wang, Q., Xu, Y., Qi, C., Liu, A., & Zhao, Y. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1702548 · Cited by 29
“When the body TREM2 level is downregulated, fewer plaque-associated microglia were seen in patients and then more amyloid plaque deposits [31].”
BackgroundMolecular Assessment of Epiretinal Membrane: Activated Microglia, Oxidative Stress and Inflammation
Vishwakarma, S., Gupta, R. K., Jakati, S., Tyagi, M., Pappuru, R. R., Reddig, K. R., Hendricks, G. M., Volkert, M. R., Khanna, H., Chhablani, J. K., et al. (2020) · Antioxidants · doi:10.3390/antiox9080654 · Cited by 29
Lin, C., Kong, Y., Chen, Q., Zeng, J., Pan, X., & Miao, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1420731 · Cited by 27
TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting
Yang, H.-W., Kim, D., Yang, Y., Bagyinszky, E., & An, S. S. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157057 · Cited by 28
“Two disulfide bridges have been identified in TREM2, between cysteine 36 and 110 and cysteine 51 and 60 (Figure 1) [1–10 , TREM2 protein is highly expressed in the brain and plays an active role in the activation of microglia in the central nervous system (CNS) homeostasis, suggesting that TREM2…”
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy
Li, G., Xu, J., Tian, X., Xiao, J., Long, J., Chen, Y., Shen, W., & Zhao, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02484-7 · Cited by 35
Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice
Bader, A. S., Gnädig, M.-U., Fricke, M., Büschgens, L., Berger, L. J., Klafki, H., Meyer, T., Jahn, O., Weggen, S., & Wirths, O. (2023) · Life · doi:10.3390/life13041053 · Cited by 33
Berberine modulates microglial polarization by activating TYROBP in Alzheimer's disease
Yu, Y., Wu, J., Jia, L., Feng, S., Qi, Z., Yu, H., Wu, Y., & Wang, S. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156237 · Cited by 27
Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy
Chen, Y., Liu, Y. A., Nguyen, K. M., Wu, J., Song, S., Lin, K., Rodrigues, P. F., Du, S., Zhou, C., Xiong, K., et al. (2026) · Science · doi:10.1126/science.ads3972 · Cited by 30
Self-citationXu, X., Du, L., Jiang, J., Yang, M., Wang, Z., Wang, Y., Tang, T., Fu, X., & Hao, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.716917 · Cited by 25
Self-citationHohsfield, L. A., Tsourmas, K. I., Ghorbanian, Y., Syage, A. R., Kim, S. J., Cheng, Y., Furman, S., Inlay, M. A., Lane, T. E., & Green, K. N. (2022) · Glia · doi:10.1002/glia.24144 · Cited by 26
Alzheimer's disease pathology in Nasu-Hakola disease brains
Satoh, J.-I., Kino, Y., Yanaizu, M., & Saito, Y. (2018) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2017.01088 · Cited by 23
“These observations suggest that TREM2/ DAP12-mediated microglial response limits diffusion and toxicity of amyloid plaques by forming a protective barrier (10,11).”
BackgroundTreatment with Bifidobacteria can suppress Aβ accumulation and neuroinflammation in APP/PS1 mice
Wu, Q., Li, Q., Zhang, X., Ntim, M., Wu, X., Li, M., Wang, L., Zhao, J., & Li, S. (2020) · PeerJ · doi:10.7717/peerj.10262 · Cited by 26
“Since bacteria can affect ENS, if they or their messengers can reach the CNS, they will have the same effect on the CNS.”
BackgroundInfluentialZinc utilization by microglia in Alzheimer’s disease
Shippy, D. C., Oliai, S. F., & Ulland, T. K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107306 · Cited by 28
Self-citationTakatori, S., Kondo, M., & Tomita, T. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00383-4 · Cited by 29
“…TREM2 is crucial for microglial Aβ phagocytosis and metabolism, it is also deeply involved in mitigating amyloid toxicity through microglial clustering around amyloid plaques and promoting plaque compaction, which reduces the exposure of toxic Aβ species to surrounding neurons [13, 19, 31, 32].”
Zhao, Y., Tian, S., Zhang, J., Cheng, X., Huang, W., Cao, G., Chang, Y., Wang, H., Nie, G., & Qiu, W. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101457 · Cited by 26
APOEε4 and risk of Alzheimer’s disease – time to move forward
Lefterov, I. M., Fitz, N. F., Lü, Y., & Koldamova, R. P. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1195724 · Cited by 25
“5 months and no difference in amyloid load at an earlier age of 5XFAD mice (Wang et al., 2016).”
BackgroundNoble, M., Scott‐Hewitt, N., & Folts, C. J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.228712 · Cited by 23
Non-genetic Heterogeneity of Macrophages in Diseases—A Medical Perspective
Gessain, G., Blériot, C., & Ginhoux, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.613116 · Cited by 25
“Adipose tissue macrophages (ATMs) are the largest immune population in adipose tissue and accumulate even more in obesity where they promote a chronic low-grade inflammation (Weisberg et al., 2003; Xu et al., 2003).”
BackgroundJury-Garfe, N., Redding-Ochoa, J., You, Y., Martínez, P., Karahan, H., Chimal-Juárez, E., Johnson, T. S., Zhang, J., Resnick, S., Kim, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02775-1 · Cited by 31
“…and humans carrying the R47H mutation in the TREM2 gene, the microglia demonstrate a markedly reduced ability to envelop amyloid deposits, decreasing compact plaque phenotypes and increasing amyloid fibril exposure to adjacent neurites, which is associated with tau hyperphosphorylation [102, 106].”
BackgroundWang, J., Du, L., Zhang, T., Chu, Y., Wang, Y., Wang, Y. T., Ji, X., Kang, Y., Cui, R., Zhang, G., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110006 · Cited by 23
“…TREM2 knockdown increases microglia-mediated inflammatory response, A β plaque deposition, and the expression of apoptotic markers of microglia around plaques, exacerbating neurodegenerative changes in AD mice (Wang et al., 2016; Yuan et al., 2016; Meilandt et al., 2020; Ruganzu et al., 2022).”
BackgroundSelf-citationTan, L. Y., Cunliffe, G., Hogan, M. P., Yeo, X. Y., Oh, C., Jin, B., Kang, J., Park, J., Kwon, M., Kim, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1380063 · Cited by 26
Immune Modulation in Alzheimer’s Disease: From Pathogenesis to Immunotherapy
Balkhi, S., Spirito, A. D., Poggi, A. D., & Mortara, L. (2025) · Cells · doi:10.3390/cells14040264 · Cited by 23
“Studies such as those by Reed-Geaghan et al. (2020) [78] and Wang et al. (2016) [79] demonstrate that plaque-associated myeloid cells in AD are derived predominantly from brain-resident microglia, with minimal contribution from circulating monocytes.”
Connections between ApoE, sleep, and Aβ and tau pathologies in Alzheimer’s disease
Sadleir, K. R., & Vassar, R. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171838 · Cited by 22
You, Y., Chen, Z., & Hu, W. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108606 · Cited by 27
Current understanding on TREM-2 molecular biology and physiopathological functions
Bharadwaj, S., Groza, Y., Mierzwicka, J. M., & Malý, P. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112042 · Cited by 25
von Saucken, V. E., Jay, T. R., & Landreth, G. E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105072 · Cited by 23
“TREM2 is necessary after plaque development to orchestrate changes in microglial phenotype, accumulation around plaques, and clearance of amyloid species (Jay et al., 2017b; Wang et al., 2016; Yuan et al., 2016).”
BackgroundInnate and adaptive immunity in neurodegenerative disease
Huang, Y., Zhang, G., Li, S., Feng, J., & Zhang, Z. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05533-4 · Cited by 26
Haynes, E. M., Ulland, T. K., & Eliceiri, K. W. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.867010 · Cited by 25
Self-citationEssex, A. L., Huot, J. R., Deosthale, P. J., Wagner, A., Figueras, J. H., Davis, A., Damrath, J. G., Pin, F., Wallace, J. M., Bonetto, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4572 · Cited by 26
“TREM2 has been shown to play a critical role in microglial response to AD pathology, being a receptor for the Aβ oligomers and dictating microglial response to plaque although not triggering phagocytosis of the plaque but forming a barrier to prevent further expansion of the plaque.((16,23,24)) Previous studies on TRE…”
BackgroundMicroglial Transforming Growth Factor-β Signaling in Alzheimer’s Disease
Vidovic, N., & Spittau, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063090 · Cited by 25
“Consequently, in AD, TREM2 is increased in the microglia surrounding amyloid deposits [82].”
BackgroundImbalance in the response of pre- and post-synaptic components to amyloidopathy
Stephen, T., Tamagnini, F., Piegsa, J., Sung, K., Harvey, J., Oliver‐Evans, A., Murray, T. K., Ahmed, Z., Hutton, M. L., Randall, A. D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50781-1 · Cited by 25
Pathways linking Alzheimer’s disease risk genes expressed highly in microglia
Hodges, A. K., Piers, T. M., Collier, D., Cousins, O., & Pocock, J. M. (2021) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2020.60 · Cited by 21
“In this model, amyloid is a protective mechanism for pathogen entrapment, and together with microglia encasement prevents further infectivity as well as Aβ toxicity, thereby avoiding the need for a much larger and potentially damaging pro-inflammatory response([75-77]).”
Alzheimer’s Disease, Sleep Disordered Breathing, and Microglia: Puzzling out a Common Link
Ulland, T. K., Ewald, A. C., Knutson, A. O., Marino, K. M., Smith, S. M. C., & Watters, J. J. (2021) · Cells · doi:10.3390/cells10112907 · Cited by 21
Self-citationMicroglia regulate cortical remyelination via TNFR1-dependent phenotypic polarization
Boutou, A., Roufagalas, I., Politopoulou, K., Tastsoglou, S., Abouzeid, M., Skoufos, G., de Juan, L. V., Ko, J. H., Kyrargyri, V., Hatzigeorgiou, A. G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114894 · Cited by 25
Fixemer, S., de la Maza, M. M., Hammer, G. P., Jeannelle, F., Schreiner, S., Gérardy, J., Boluda, S., Mirault, D., Mechawar, N., Mittelbronn, M. G. A., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02857-8 · Cited by 25
“Microglial accumulation in a rosette-like conformation around Aβ core plaques in post-mortem human AD samples or mouse models [3, 11, 19] has been particularly studied [43, 104, 109].”
TREM2 in Neurodegenerative Diseases: Mechanisms and Therapeutic Potential
Li, L., Zheng, X., Ma, H., Zhu, M., Li, X., Sun, X., & Feng, X. (2025) · Cells · doi:10.3390/cells14171387 · Cited by 25
“Early studies on 4-month-old 5xFAD mice revealed similar levels of microgliosis and A β deposition between Trem2 -deficient and Trem2 -sufficient mice [109].”
Hu, B., Geng, C., Guo, F., Liu, Y., Zong, Y.-C., & Hou, X. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.003 · Cited by 21
Al‐Onaizi, M., Thériault, P., Lecordier, S., Préfontaine, P., Rivest, S., & ElAli, A. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.07.016 · Cited by 20
Ayyubova, G. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.15914 · Cited by 23
Araki, W. (2023) · Cells · doi:10.3390/cells12101386 · Cited by 20
“TREM2 is suggested to play a protective role by enabling microglia to surround Aβ plaques and alter their structure, thereby limiting neuritic damage [40,41].”
BackgroundŠpanić, E., Leko, M. B., Horvat, L. L., Brgić, K., Vogrinc, Ž., Boban, M., Klepac, N., Borovečki, F., & Šimić, G. (2023) · Neurology International · doi:10.3390/neurolint15030053 · Cited by 21
“The protective effect of increased TREM2 expression against AD symptoms has previously been reported [10].”
BackgroundYe, H., Li, P., Zhai, Q., Yang, S., Yang, S., Sun, Y., Wu, S., Huang, R., 陈齐兴, & Fang, X. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111178 · Cited by 20
Alzheimer’s Disease Genetics: A Dampened Microglial Response?
Chatila, Z. K., & Bradshaw, E. M. (2021) · The Neuroscientist · doi:10.1177/10738584211024531 · Cited by 25
Welcome, M. O. (2018) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000492491 · Cited by 22
TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo
Lee-Gosselin, A., Jury-Garfe, N., You, Y., Dabin, L., Soni, D., Dutta, S., Rochet, J.-C., Kim, J., Oblak, A. L., & Lasagna-Reeves, C. A. (2023) · Cells · doi:10.3390/cells12121597 · Cited by 23
“TREM2-deficient microglia have also been shown to have an impaired proliferative ability and decreased viability [11,47].”
BackgroundFunction and mechanism of TREM2 in bacterial infection
Wu, Z., Yang, S., Fang, X., Shu, Q., & Chen, Q. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011895 · Cited by 21
Brain macrophages in vascular health and dysfunction
Bijnen, M., Sridhar, S., Keller, A., & Greter, M. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.11.012 · Cited by 22
Neuroinflammation and galectins: a key relationship in neurodegenerative diseases
Hernández, E. R., Olvera, B. A., González, D. C., Marín, O. G., Mercado, D. P., Gil, L. V., Hernández-Zimbrón, L. F., Sánchez‐Salgado, J. L., Limón, I. D., & Zenteno, E. (2022) · Glycoconjugate Journal · doi:10.1007/s10719-022-10064-w · Cited by 23
The Hidden Role of Non-Canonical Amyloid β Isoforms in Alzheimer’s Disease
Busch, L., Eggert, S., Endres, K., & Bufe, B. (2022) · Cells · doi:10.3390/cells11213421 · Cited by 22
Phenomic Microglia Diversity as a Druggable Target in the Hippocampus in Neurodegenerative Diseases
Lana, D., Magni, G., Landucci, E., Wenk, G. L., Pellegrini-Giampietro, D. E., & Giovannini, M. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813668 · Cited by 20
Tolédano, A., Rodríguez‐Casado, A., Álvarez, M., & Toledano‐Díaz, A. (2024) · Brain Sciences · doi:10.3390/brainsci14111101 · Cited by 21
The Innate and Adaptive Immune Cells in Alzheimer’s and Parkinson’s Diseases
Huang, B., Zhenxin, Y., Chen, S., Tan, Z., Zong, Z., Zhang, H., & Xiong, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1315248 · Cited by 23
“For example, a missense mutation (R47H) in triggering receptor expressed in myeloid cells 2 (TREM2), a cell surface protein highly and selectively expressed on microglia, was found to increase the risk of AD approximately three-fold [54, 55].”
BackgroundAmyloid Beta in Alzheimer's Disease: Mechanisms, Biomarker Potential, and Therapeutic Targets
Ahmadi, S., Khaledi, S., Ahmadi, K., & Hassanzadeh, K. (2025) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70688 · Cited by 22
“Previous studies demonstrated the protective role of TREM2 in response to amyloid pathology [149].”
Joshi, P., Riffel, F., Kumar, S., Villacampa, N., Theil, S., Parhizkar, S., Haass, C., Colonna, M., Heneka, M. T., Arzberger, T., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01263-x · Cited by 18
Self-citationAllogenic microglia replacement: A novel therapeutic strategy for neurological disorders
Rao, Y., & Peng, B. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.02.025 · Cited by 20
He, Y., YANG, K. Y., Zhang, L., Zhan, M., Xia, X., Wang, H.-F., Xie, Y., Huang, L., Yang, N., Zheng, Y., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121981 · Cited by 20
Alzheimer’s disease: an axonal injury disease?
Liang, D., & Zhang, Z. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1264448 · Cited by 23
Peripheral HMGB1 is linked to O3 pathology of disease‐associated astrocytes and amyloid
Ahmed, C., Greve, H. J., Garza-Lombó, C., Malley, J. A., Johnson, J., Oblak, A. L., & Block, M. L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13825 · Cited by 20
Lim, S., Tran, D. N., Zumkehr, J., Chen, C., Ghiaar, S., Kieu, Z., Villanueva, E., Gallup, V., Rodríguez‐Ortiz, C. J., & Kitazawa, M. (2018) · Glia · doi:10.1002/glia.23522 · Cited by 21
“…are commonly observed around Aβ plaques in postmortem human AD brains (Itagaki, McGeer, Akiyama, Zhu, & Selkoe, 1989; Mackenzie & Hao, 1995; Wegiel & Wisniewski, 1990) and in AD mouse models, including J20 mice (Fu, Rusznák, Kwok, Kim, & Paxinos, 2014; Kim et al., 2013), we exam- ined whether Hck…”
BackgroundThe Role of TREML2 in Alzheimer’s Disease
Wang, S., Gong, P., Yan, E., Zhang, Y., & Jiang, T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200406 · Cited by 19
“…[21, 46]; regulates microglial proliferation [14] regulates microglial proliferation [47], polarization [48], migration [49–51] and clustering [52, 53]; regulates microglial energy metabolism [54, 55] could specifically bind to TREML2 and thus activate its downstream signaling [29], whereas…”
Dynamic insights into the effects of nonsynonymous polymorphisms (nsSNPs) on loss of TREM2 function
Dash, R., Munni, Y. A., Mitra, S., Choi, H. J., Jahan, S. I., Chowdhury, A., Jang, T. J., & Moon, I. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13120-5 · Cited by 22
Torso, M., Ridgway, G. R., Hardingham, I., Schwarz, A. J., & Chance, S. A. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.59 · Cited by 19
“One possible interpretation of this dynamic progression is that microglia initially form a barrier around the plaque, sTREM2 and PGRN released by microglia remain in the plaque until the barrier fails, followed by increased concentration in the CSF of sTREM2 and PGRN (37, 45).”
BackgroundLong, J., Zhang, J., Zeng, X., Wang, M., & Wang, N. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70101 · Cited by 19
Amyloid β-Induced Inflammarafts in Alzheimer’s Disease
Ding, S., Choi, S., & Miller, Y. I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104592 · Cited by 24
“For instance, in AD models, TREM2 deficiency impairs microglial clustering around A β plaques, exacerbating disease pathology by reducing A β clearance and increasing neuroinflammation [71,72].”
From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease
Agnello, L., Gambino, C. M., Ciaccio, A. M., Cacciabaudo, F., Massa, D., Masucci, A., Tamburello, M., Vassallo, R., Midiri, M., Scazzone, C., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080580 · Cited by 26
“Tau protein is essential for stabilizing microtubules in the neurons of the central nervous system (CNS) [11].”
Microglia in Brain Aging and Age-Related Diseases: Friends or Foes?
Ishikawa, K., Fujikawa, R., Okita, K., Kimura, F., Watanabe, T., Katsurabayashi, S., & Iwasaki, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311494 · Cited by 19
“The TREM2–APOE axis underlies this DAMs phenotype [74,99].”
InfluentialSanchez-Molina, P., Rosmus, D.-D., Brownell, D., Meral, M., Gohlich, C., Pratapa, A., Peymanfar, Y., Whitley, A., Hou, Y., Nikulina, N., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02267-3 · Cited by 24
“This contrasts with the traditional view that blood-derived cells do not infiltrate AD brain, as shown in parabiosis studies of 5xFAD mice 57 .”
An overview on microglial origin, distribution, and phenotype in Alzheimer's disease
Islam, R., Choudhary, H. H., Rajan, R. G., Vrionis, F. D., & Hanafy, K. A. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30829 · Cited by 20
“Many evidence showed that TREM2 is essential for the microglial response to Ab plaques (Y. Wang et al., 2016).”
BackgroundNeuroimmune interactions in Alzheimer's disease—New frontier with old challenges?
Prokop, S., Lee, V. M. ‐., & Trojanowski, J. Q. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.10.002 · Cited by 19
Toomey, C. E., Heywood, W., Benson, B. C., Packham, G., Mills, K. A., & Lashley, T. (2020) · Brain Pathology · doi:10.1111/bpa.12842 · Cited by 18
“Whereas, in mouse models overexpressing TREM2, decreases in amyloid plaque deposition were observed, and TREM2 deficient models showed conflicting results on the amount of amyloid load between cortical and hippocampal regions (20-21,58,59).”
BackgroundPLCG2 modulates TREM2 expression and signaling in response to Alzheimer's disease pathology
Messenger, E. J., Baar, S. A., Bedford, L. M., Tsai, A. P., Lin, P. B., Ferguson, C. A., Xu, G., Wallace, A., Landreth, G. E., Lamb, B. T., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70231 · Cited by 19
“41 , 60 Previous work has shown that PLCG2 depletion inhibits TREM2 signaling in response to TREM2 ligands in vitro.”
DAP12 interacts with RER1 and is retained in the secretory pathway before assembly with TREM2
Liu, Y., Theil, S., Ibach, M., & Walter, J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05298-w · Cited by 18
MicroRNAs Modulating Neuroinflammation in Parkinson's disease
Saadh, M. J., Muhammad, F. A., Singh, A., Mustafa, M. A., Zuhairi, R. A. H. A., Ghildiyal, P., Hashim, G. M., Alsaikhan, F., Khalilollah, S., & Akhavan‐Sigari, R. (2024) · Inflammation · doi:10.1007/s10753-024-02125-z · Cited by 16
Ennerfelt, H. E., Holliday, C., Shapiro, D. A., Zengeler, K. E., Bolte, A. C., Ulland, T. K., & Lukens, J. R. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303760120 · Cited by 17
“The stimulation of microglial recruitment and proliferation in response to AD pathology is well characterized (22, 60), however, the loss of CARD9 appears to significantly enhance microglial mobilization to Aβ plaques while concurrently exacerbating Aβ load in the cortex of 5xFAD mice.”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., Cella, M., Grutzendler, J., DeMattos, R. B., Cirrito, J. R., Holtzman, D. M., & Colonna, M.
- Affiliations
- Eli Lilly (United States) (US)
- Washington University in St. Louis (US)
- Yale University (US)
- Corresponding author
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-04-18
- Volume
- 213
- Issue
- 5
- Pages
- 667-675
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4854736
- OpenAlex
- W2339534121
- Cited by
- 840
- References
- 32
- Citations by year
- 2026: 62 · 2025: 76 · 2024: 86 · 2023: 106 · 2022: 114 · 2021: 102 · 2020: 93 · 2019: 73 · 2018: 61 · 2017: 50 · 2016: 16
- FWCI
- 36.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Eli Lilly and Company
- National Institutes of Health (RF1 AG05148501, 5T32CA009547-30, AG047644)
- National Multiple Sclerosis Society (RG4687A1/1)
- Cure Alzheimer’s Fund
- JPB Foundation
- Knight Alzheimer’s Disease Research Center (P50 AG005681-30)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- TREM2, microglia, amyloid plaques, Alzheimer's disease, parabiosis, 5xFAD mice, TREM2 deficiency, lipid microenvironment, peripheral blood monocytes
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Humans, Membrane Glycoproteins, Monocytes, Receptors, Immunologic, Amyloid beta-Peptides, Neurites, Microglia, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.